France dilutes comparative trial demand, axes class actions as reform bill proceeds
This article was originally published in Scrip
The bill on strengthening the French drug regulatory system has returned to the lower house for a second reading, with several changes including one that waters down the senate's proposal to require comparative trials against the gold-standard comparator for reimbursement purposes.
You may also be interested in...
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.